Motavizumab biosimilar

Drug Profile

Motavizumab biosimilar

Alternative Names: 3rd-generation anti-RSV MAb - MedImmune; MEDI-557; Mota-YTE; Motavizumab-YTE; RSV-YTE

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 20 Jul 2017 MedImmune terminates a phase I trial for Respiratory syncytial virus infections in United Kingdom as it was determined to not be feasible to complete enrolment and the study within the required timeline and budget (IV) (NCT01475305)
  • 30 Jun 2013 Discontinued - Phase-I for Respiratory syncytial virus infections in USA and United Kingdom (IV)
  • 01 Apr 2013 MedImmune completes a phase I trial in healthy volunteers in the United Kingdom (NCT01475305)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top